- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04833725
Screening and Early Warning of Chronic Obstructive Pulmonary Disease Combined With Sleep Respiratory Disease Based on Medical Internet of Things
April 2, 2021 updated by: Peking University Third Hospital
Chronic obstructive pulmonary disease (COPD) is a common disease that endangers people's health, causing severe economic and treatment burdens.
Sleep breathing disease, as a complication of COPD, increases the hospitalization rate and mortality of COPD.
At present, community doctors have insufficient knowledge of COPD and its complications, and they also lack standardized screening and related disease management capabilities.
This trail intends to use IoT medical technology to screen for COPD combined with sleep breathing diseases.
It can establish a two-way referral channel between primary community hospitals and higher-level hospitals, which provides early warning services for COPD combined with sleep breathing diseases.
This trial explores the impact of sleep breathing disease on COPD's acute exacerbation, which improves the understanding of COPD patients combined with sleep breathing diseases.
It also improves COPD management and its complications control at the community-level and reduces COPD patients' potential risks and treatment burdens.
It also explores tiered diagnosis and treatment models for COPD, promotes the construction of intelligent IoT infrastructure, and enhances standardized diagnosis and treatment of COPD at the grassroots level in China.
Study Overview
Detailed Description
This study is a multi-center joint study, which mainly consists of two parts.
First, a cross-sectional observational study was adopted to recruit patients with stable COPD in multiple centers.
The COPD's diagnostic criteria follow diagnostic guidelines in China, and the patients were selected among 40-80 years old.
Note that we excluded patients who cannot use IoT's mobile applications and cannot complete sleep monitoring and follow-up visits.
All patients collect sleep monitoring information through wearable devices, together with demographic characteristics, pulmonary function tests, blood routines, biochemistry, electrocardiogram, chest radiograph, COPD assessment scale, modified British Medical Research Association dyspnea index, St. George's Quality of Life Questionnaire, Sleep Apnea Clinical Score, Berlin Questionnaire, Epworth Sleepiness Scale, Etc.
This study estimates patient health status from the collected information, then diagnoses sleep apnea and calculates sleep apnea prevalence.
Specifically, we build standards from the analysis of sleep monitoring information, and we form an OSA screening model by applying machine learning algorithms.
Second, we establish a COPD cohort joined with sleep breathing disease, where we select COPD patients meeting the diagnostic criteria for sleep breathing disease.
All patients use wearable devices and IoT technology for information collection and data management.
We also build the early warning platform, and it allows flexible adjustment on the COPD plan according to individual differences and community differences.
This tudy requires followed up visit once a month.
By observing the number of hospitalizations, the incidence of acute exacerbations, and other secondary observation indicators of COPD patients, the early warning platform can analyze COPD's acute exacerbations combined with sleep respiratory disease.
We develop the disease and prognosis model for COPD patients with SAO by applying machine learning algorithms on the previous platform.
Study Type
Observational
Enrollment (Anticipated)
680
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Beijing, China
- Recruiting
- Peking University Third Hospital
-
Contact:
- Yahong Chen
- Phone Number: +8601082266699
- Email: chenyahong@vip.sina.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
40 years to 80 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
Patients with stable COPD from Peking University Third Hospital, Beijing Haidian Hospital, Beijing Zhongguancun Hospital, Beixiaguan Community Health Service Center and Huayuan Road Community Health Service Center.
Description
Inclusion Criteria:
The diagnostic criteria for COPD are in line with the diagnostic guidelines for COPD in China from 40 to 80 years old.
Exclusion Criteria:
Patients who cannot use IoT's mobile applications and cannot complete sleep monitoring and follow-up visits.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
COPD combined with OSA
All patients collect sleep monitoring information through wearable devices, together with demographic characteristics, pulmonary function tests, blood routines, biochemistry, electrocardiogram, chest radiograph, COPD assessment scale, modified British Medical Research Association dyspnea index, St. George's Quality of Life Questionnaire, Sleep Apnea Clinical Score, Berlin Questionnaire, Epworth Sleepiness Scale, Etc.
This study estimates patient health status from the collected information, then diagnoses sleep apnea and calculates sleep apnea prevalence.
|
All patients use wearable devices and IoT technology for information collection and data management.
Specifically, we build standards from the analysis of sleep monitoring information, and we form an OSA screening model by applying machine learning algorithms.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Build the screening model of COPD combined with OSA - 12 months
Time Frame: 12 months
|
We build the screening model of COPD combined with OSA by applying machine learning techniques to the monitoring information.
And we evaluate its effectiveness on the patient status estimation, where the morbidity of COPD with OSA is measured through the screening model.
|
12 months
|
|
Build the prognosis model of COPD combined with OSA - 12 months
Time Frame: 12 months
|
We build the prognosis model of COPD combined with OSA and integrate it into the early warning platform.
It observes the incidence rate of acute exacerbation COPD and other indexes
|
12 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
January 1, 2020
Primary Completion (ANTICIPATED)
December 31, 2021
Study Completion (ANTICIPATED)
December 31, 2022
Study Registration Dates
First Submitted
April 2, 2021
First Submitted That Met QC Criteria
April 2, 2021
First Posted (ACTUAL)
April 6, 2021
Study Record Updates
Last Update Posted (ACTUAL)
April 6, 2021
Last Update Submitted That Met QC Criteria
April 2, 2021
Last Verified
April 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2020-2Z40917
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on COPD
-
University Medical Center GroningenCompleted
-
Insel Gruppe AG, University Hospital BernUniversity Hospital, Geneva; Cantonal Hospital St. Gallen, SwitzerlandNot yet recruiting
-
Istituto Nazionale di Ricovero e Cura per AnzianiRecruiting
-
Bio-Sensing Solutions S.L. (DyCare)Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau; Centre...Recruiting
-
Sir Run Run Shaw HospitalRecruiting
-
The First Affiliated Hospital of Guangzhou Medical...Recruiting
-
Association des Réseaux BronchioliteLaboratoire Système et Matériaux pour la Mécatronique (SYMME)Recruiting
-
Polytechnic Institute of PortoNippon Gases PortugalRecruiting
-
China-Japan Friendship HospitalNot yet recruiting
-
Icahn School of Medicine at Mount SinaiNational Heart, Lung, and Blood Institute (NHLBI)Recruiting
Clinical Trials on wearable devices
-
Taipei Medical UniversityRecruitingSedentary Lifestyle | Social Media | Wearable Technology | Health Behavior Change | ChatbotTaiwan
-
Affiliated Hospital of Nantong UniversityRecruitingSmoking | Hypertension | Diabetes | Atrial Fibrillation | Dyslipidemia | Physical Inactivity | Obesity and OverweightChina
-
Tri-Service General HospitalRecruiting
-
McGill University Health Centre/Research Institute...CompletedChronic Obstructive Pulmonary Disease | Chronic Obstructive Pulmonary Disease ExacerbationCanada
-
University Hospital, Basel, SwitzerlandCompletedAtrial Fibrillation (AF)Switzerland
-
Huashan HospitalRecruitingMajor Depressive Disorder (MDD) | Anxiety Disorder | Alcohol Use Disorder (AUD)China
-
Boston Scientific CorporationCompletedBlood Pressure | Health Behavior
-
National Taiwan University HospitalCompletedObstructive Sleep Apnea SyndromeTaiwan
-
McGill University Health Centre/Research Institute...Restech SrlRecruiting
-
The First Affiliated Hospital of Guangzhou Medical...RecruitingNon Small Cell Lung CancerChina